| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IGSF6 |
| Uniprot No | O95976 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 29-241aa |
| 氨基酸序列 | TLSVTQPWYLEVDYTHEAVTIKCTFSATGCPSEQPTCLWFRYGAHRPENLCLDGCKSEADKFTVREALKENQVSLTVNRVTSNDSAIYICGIAFPSVPEARAKQTGGGTTLVVREIKLLSKELRNFLTALVSLLSVYVTGVCVAFILLSKSKSNPLRNKKIKEDSQKKKSARRIFQEIAQELYHKRHVETNQQSEKDNNTYENRRVLSNYERP |
| 分子量 | 49.17 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人IGSF6蛋白的3条示例参考文献(内容为虚构，仅作格式参考)：
1. **文献名称**：*Characterization of recombinant human IGSF6 protein and its role in T-cell regulation*
**作者**：Smith A, et al.
**摘要**：本研究成功在大肠杆菌中表达并纯化了重组人IGSF6胞外结构域蛋白，发现其可通过抑制T细胞受体(TCR)信号通路调节T细胞活化，提示其在自身免疫疾病中的潜在治疗价值。
2. **文献名称**：*Recombinant IGSF6 interacts with CD155 in tumor microenvironment: Implications for cancer immunotherapy*
**作者**：Zhang L, et al.
**摘要**：通过哺乳动物细胞表达系统制备重组人IGSF6蛋白，证实其与肿瘤细胞表面CD155的结合能力，揭示了IGSF6可能通过阻断免疫检查点相互作用增强抗肿瘤免疫反应。
3. **文献名称**：*Structural and functional analysis of IGSF6 in dendritic cell maturation*
**作者**：Brown K, et al.
**摘要**：该研究解析了重组人IGSF6蛋白的晶体结构，并证明其通过TLR4依赖性途径抑制树突状细胞成熟，为靶向IGSF6的免疫调节策略提供了新方向。
注：以上文献为模拟示例，实际研究中请通过PubMed、Web of Science等平台检索真实发表的论文。
Recombinant human IGSF6 protein is a genetically engineered transmembrane glycoprotein belonging to the immunoglobulin superfamily (IgSF). It contains extracellular immunoglobulin-like domains involved in cell-cell interactions and immune regulation. IGSF6 is predominantly expressed in immune cells, particularly T lymphocytes and dendritic cells, and plays a role in modulating immune responses. Studies suggest its involvement in T-cell activation and apoptosis regulation through interactions with ligands like CD226. potentially influencing inflammatory signaling pathways.
Research on IGSF6 has expanded due to its association with immune-related pathologies. Altered IGSF6 expression has been observed in cancers, autoimmune disorders, and viral infections, highlighting its dual role in immune activation and tolerance. Recombinant IGSF6 is widely used to study these mechanisms, including its structural-functional relationships and interactions with immune checkpoints. Its therapeutic potential is being explored in antibody development, vaccine design, and targeted immunotherapy, particularly for diseases involving dysregulated T-cell activity. However, functional insights remain preliminary, necessitating further studies to clarify its precise biological roles and translational applications.
×
